1 month ago
24
Brendan Coffey, The Motley Fool
Tue, July 7, 2026 astatine 9:56 AM CDT 7 min read
Genetic engineering and weight-loss innovation person go focal points for modern healthcare investors. Choosing betwixt CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) depends connected your appetite for hazard and your content successful their chiseled aesculapian breakthroughs.
CRISPR Therapeutics uses gene-editing exertion to code diseases astatine their familial source, portion Viking focuses connected metabolic conditions specified arsenic obesity that impact millions globally. Both companies correspond high-potential opportunities wrong the biotechnology space, though they presently beryllium astatine precise antithetic stages of their respective commercialized journeys.
The lawsuit for CRISPR Therapeutics
CRISPR Therapeutics focuses connected processing transformative gene-based medicines utilizing its proprietary CRISPR/Cas9 platform. The institution precocious achieved a large milestone with the commercialized motorboat of Casgevy, a attraction for sickle compartment illness and transfusion-dependent beta thalassemia. It operates nether a strategical collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages planetary manufacturing and commercialization. Customer attraction similar this adds a furniture of hazard to the business, arsenic CRISPR Therapeutics relies connected this spouse for 60% of its profits and losses.
In FY 2025, gross was astir $3.5 million, representing a alteration of astir 90% from the anterior year. This diminution is mostly owed to the modulation from receiving one-time milestone payments to gathering retired semipermanent commercialized gross streams from its approved products. The institution reported a nett nonaccomplishment of adjacent to $581.6 million. Investing successful biotech stocks requires an knowing of however these companies determination from aboriginal probe to planetary commercialization.
As of its December 2025 equilibrium sheet, the debt-to-equity ratio was astir 0.2x. This ratio measures full indebtedness comparative to the equity shareholders person successful the company, with a little fig indicating little reliance connected borrowed money. Free currency travel was antagonistic $345.9 million, representing the magnitude of currency a institution generates aft paying for superior expenditures.
The lawsuit for Viking Therapeutics
Viking Therapeutics is simply a clinical-stage biopharmaceutical institution that develops therapies for metabolic and endocrine disorders. Its superior absorption is connected obesity and liver diseases, which are immoderate of the fastest-growing areas successful the modern healthcare market. The institution presently lacks its ain commercialized infrastructure and depends connected a Master License Agreement with Ligand Pharmaceuticals (NASDAQ:LGND) for its halfway pipeline assets. It besides uses third-party manufacturers, specified as CordenPharma, to nutrient its cause candidates for ongoing objective trials.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·